The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 15, 2020

Filed:

Apr. 28, 2016
Applicant:

University-industry Cooperation Group of Kyung Hee University, Gyeonggi-do, KR;

Inventors:

Tae Young Yune, Seoul, KR;

Hyung-Hwan Baik, Seoul, KR;

Jee Youn Lee, Seoul, KR;

Sam Kim, Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/375 (2006.01); A61K 31/138 (2006.01); A23L 33/10 (2016.01); A23L 33/15 (2016.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/375 (2013.01); A23L 33/10 (2016.08); A23L 33/15 (2016.08); A61K 9/0053 (2013.01); A61K 31/138 (2013.01); A23V 2002/00 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition for the prevention and treatment of blood-brain barrier disorder and central nervous system diseases containing fluoxetine and vitamin C as active ingredients. Specifically, when low concentration of fluoxetine and vitamin C, which did not show any improved effect on the blood-brain barrier disorder and disruption of blood-spinal cord barrier when administered alone, were mixed and co-administered to an animal model with spinal cord injury and transient global ischemia, the co-administration significantly increased the effect of inhibiting the increase of permeability of blood-spinal cord barrier and the effect of inhibiting MMP-9 activation and the effect of alleviating the influx of blood cells in an animal model with spinal cord injury; and the effect of inhibiting the disruption of blood-brain barrier and the effect of recovering memory in a transient global ischemia animal model, compared to the single administration of fluoxetine or vitamin C at the same concentration. The results indicate the synergy effect and the decrease of side effects by the co-administration of the compound at a low concentration, and thus fluoxetine and vitamin C of the present invention can be effectively used as active ingredients for a pharmaceutical composition for the prevention and treatment blood-brain barrier disorder and central nervous system diseases.


Find Patent Forward Citations

Loading…